Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiated Fields Or Outside Previously Irradiated Fields.
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2012
At a glance
- Drugs OSI 211 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 17 Sep 2005 New trial record.